Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,013.0 million
Deal Type : Collaboration
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
Details : Through the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $13.0 million
April 29, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,013.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Cajal Neuroscience
Deal Size : Undisclosed
Deal Type : Collaboration
Creyon Bio and Cajal Partner to Develop Oligonucleotides for Neurological Diseases
Details : Under the collaboration, the companies are developing antisense oligonucleotides (ASOs) leveraging the powerful Creyon™ Platform for multiple neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Cajal Neuroscience
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : DCVC Bio
Deal Size : $40.0 million
Deal Type : Series A Financing
Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients
Details : The proceeds of financing will support continued optimization of the Creyon Platform, expanding the team, and laying the foundations for a diverse internal pipeline. Creyon’s drug development platform creates purpose-built data sets orders of efficient...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : DCVC Bio
Deal Size : $40.0 million
Deal Type : Series A Financing